John Bishop - Momenta Pharmaceuticals Senior Vice President - Pharmaceutical Sciences

President

Dr. John E. Bishop Ph.D. is the Senior Vice President Pharmaceutical Sciences of Momenta Pharmaceuticals Inc since December 2006. He served as our Vice President Pharmaceutical Sciences and Manufacturing from November 2004 to December 2006 since 2006.
Age 53
Tenure 18 years
Professional MarksMBA
Phone617 621-0431
Webwww.momentapharma.com
Bishop received his B.S. magna cum laude in Chemistry and German from Tufts University, his Ph.D. in Organic Chemistry from UC Berkeley and his M.B.A. from Northeastern University.

Momenta Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (30.56) % which means that it has lost $30.56 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (64.36) %, meaning that it created substantial loss on money invested by shareholders. Momenta Pharmaceuticals' management efficiency ratios could be used to measure how well Momenta Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 37.09 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Momenta Pharmaceuticals has a current ratio of 6.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Momenta Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Momenta Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Momenta Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Momenta to invest in growth at high rates of return. When we think about Momenta Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Rick NechioFresh Grapes LLC
46
Ricardo MoreiraAnheuser Busch Inbev
50
Ricardo TadeuAnheuser Busch Inbev
48
Reinald SiswantoVita Coco
33
Joao NevesAnheuser Busch Inbev
49
Emily WhittakerCimpress NV
N/A
Stuart MacFarlaneAnheuser Busch Inbev
50
Mauricio ArboledaAnheuser Busch Inbev
47
Jean JereissatiAnheuser Busch Inbev
46
Sean QuinnCimpress NV
45
Graham StaleyAnheuser Busch Inbev
N/A
Lawrence GoldCimpress NV
47
Katryn BlakeCimpress NV
43
Jean NetoAnheuser Busch Inbev
50
Jan CrapsAnheuser Busch Inbev
47
Luiz EdmondAnheuser Busch Inbev
49
Michel DoukerisAnheuser Busch Inbev
51
Carlos LisboaAnheuser Busch Inbev
55
Ashley HubkaCimpress NV
42
Jason WarnerAnheuser Busch Inbev
48
Donny HartantoVita Coco
37
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. As of September 30, 2020, Momenta Pharmaceuticals, Inc. operates as a subsidiary of Johnson Johnson. Momenta Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 118 people. Momenta Pharmaceuticals (MNTA) is traded on NASDAQ Exchange in USA and employs 118 people.

Management Performance

Momenta Pharmaceuticals Leadership Team

Elected by the shareholders, the Momenta Pharmaceuticals' board of directors comprises two types of representatives: Momenta Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Momenta. The board's role is to monitor Momenta Pharmaceuticals' management team and ensure that shareholders' interests are well served. Momenta Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Momenta Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Bennett Shapiro, Independent Director
James Anderson, Senior Vice President - Pharmaceutical Sciences
Craig Wheeler, CEO and President and Executive Director
Georges Gemayel, Director
Matthew Ottmer, COO
Alejandra Carvajal, Chief Legal Officer, General Counsel and Secretary
Elizabeth Stoner, Independent Director
Michelle Robertson, CFO, Principal Financial Officer and Principal Accounting Officer
John Bishop, Senior Vice President - Pharmaceutical Sciences
JoseCarlos GutierrezRamos, Director
Bruce Leicher, Senior Vice President General Counsel, Secretary
James Sulat, Independent Chairman of the Board
Corey Fishman, Director
Jim Anderson, Senior Vice President - Pharmaceutical Sciences
Santiago Arroyo, Senior Vice President Development and Chief Medical Officer
James Roach, Senior Vice President - Development, Chief Medical Officer
Young Kwon, Senior Vice President - Corporate Development and Strategy
Bruce Downey, Independent Director
JoAnn Beltramello, Senior Vice President - Human Resources
Steven Gilman, Director
Anthony Manning, Senior Vice President - Research
Marsha Fanucci, Independent Director
Ganesh Kaundinya, Co-Founder, Chief Scientific Officer and Sr. VP of Research
Ian Fier, Senior Vice President - Program and Project Management
Richard Shea, CFO, Sr. VP and Treasurer
Michael Franken, President - Biosimilars Business, Senior Vice President
Thomas Koestler, Independent Director
Scott Storer, CFO, Senior Vice President

Momenta Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Momenta Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Momenta Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Momenta Pharmaceuticals' short interest history, or implied volatility extrapolated from Momenta Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Consideration for investing in Momenta Stock

If you are still planning to invest in Momenta Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Momenta Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges